Skip to main content
Shanghai ZJ Bio-Tech Co., Ltd logo

Shanghai ZJ Bio-Tech Co., Ltd — Investor Relations & Filings

Ticker · 688317 ISIN · CNE100005DB6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 546 across all filing types
Latest filing 2025-05-15 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 688317

About Shanghai ZJ Bio-Tech Co., Ltd

https://m.liferiver.com.cn/

Shanghai ZJ Bio-Tech Co., Ltd., operating under the brand Liferiver, specializes in the development, manufacture, and distribution of molecular diagnostic reagents and equipment. The company’s core expertise lies in real-time PCR technology, providing a comprehensive portfolio of over 400 diagnostic kits. These solutions target a broad spectrum of infectious diseases, including viral hepatitis, respiratory infections, sexually transmitted diseases, and zoonotic pathogens. Beyond clinical diagnostics, the company offers specialized kits for food safety testing and veterinary health monitoring. Its products are utilized by clinical laboratories, hospitals, and public health institutions worldwide. Many diagnostic assays have achieved international recognition through CE marking and World Health Organization (WHO) listings. The company focuses on delivering high-sensitivity, high-specificity molecular tools to facilitate rapid pathogen detection and disease management.

Recent filings

Filing Released Lang Actions
之江生物：关于召开2024年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2024 annual performance explanation meeting (业绩说明会) by Shanghai Zhijiang Bio-technology Co., Ltd. It includes the meeting time, location, participants, and how investors can participate and ask questions. It references that the 2024 annual report was already published on April 25, 2025, and this meeting is to explain and discuss the results. The document does not contain actual financial statements or detailed financial data but is an announcement of an investor presentation event focused on discussing the annual results. Therefore, it fits the category of Investor Presentation (IP). The document length is short (1473 characters), and it is not a report publication announcement or regulatory filing. Hence, the classification is Investor Presentation (IP) with high confidence.
2025-05-15 Chinese
之江生物：关于2025年第二次以集中竞价交易方式首次回购股份暨回购进展公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Shanghai Zhijiang Bio-Technology Co., Ltd. regarding the progress of its second share repurchase plan via centralized bidding. It details the repurchase scheme, including the amount, price range, purpose, and progress of shares repurchased. The document is focused on the company's buyback of its own shares and does not contain financial statements or earnings data. It is not a full financial report but a specific update on share repurchase activity. Therefore, it fits the category of Transaction in Own Shares (POS). The document length is short and it is a direct announcement of repurchase progress, not a report publication or regulatory filing. Confidence is high due to clear keywords like '回购股份' (share repurchase), '回购进展公告' (repurchase progress announcement), and detailed repurchase data.
2025-05-14 Chinese
之江生物：关于2025年第二次以集中竞价交易方式回购股份的回购报告书
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from Shanghai Zhijiang Bio-Technology Co., Ltd. regarding a share repurchase plan. It includes specifics about the repurchase amount, price limits, funding sources, purpose, implementation procedures, risks, and historical repurchase activities. The document is not a financial report or earnings release but a comprehensive disclosure about the company's share buyback program. It is not a brief announcement of voting results or a regulatory filing of a different nature. The content matches the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares. The document length and detail confirm it is the report itself, not just an announcement of a report publication.
2025-05-08 Chinese
之江生物：2024年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled "2024 年年度股东大会会议资料" which translates to "2024 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda items, meeting instructions, reports to be discussed at the AGM, including the board work report, financial reports, annual report summary, director remuneration proposals, auditor reappointment, asset impairment provisions, and independent director reports. The document is clearly a comprehensive set of materials prepared for the 2024 Annual General Meeting of shareholders. It is not the annual report itself, nor is it a brief announcement or voting results. The length (15,000 characters) and content indicate it is the meeting materials presented at the AGM. Therefore, the document fits the category of AGM Information (AGM-R).
2025-05-08 Chinese
之江生物：关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shanghai Zhijiang Biotechnology Co., Ltd. regarding the top ten shareholders and top ten unrestricted shareholders before a share repurchase. It references a board meeting approving a share repurchase plan and provides detailed shareholding information. The content focuses on shareholding changes related to a share buyback, not on financial results, management changes, or other report types. The document length is short (1642 characters) and it is a formal announcement of shareholding status in relation to a share repurchase. This fits the category of Transaction in Own Shares (POS), which covers company buyback or sale of its own shares.
2025-05-08 Chinese
国泰海通证券股份有限公司关于上海之江生物科技股份有限公司首次公开发行股票并在科创板上市之保荐总结报告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "保荐总结报告书" which translates to "Sponsorship Summary Report" related to the initial public offering (IPO) and listing of Shanghai Zhijiang Biotechnology Co., Ltd. on the STAR Market. It details the sponsorship institution's (Guotai Haitong Securities Co., Ltd.) responsibilities, continuous supervision period, compliance with regulatory requirements, and evaluation of the issuer's cooperation and information disclosure. The document includes detailed descriptions of the sponsorship work during the IPO process and continuous supervision, as well as opinions on the use of raised funds. It is a comprehensive report summarizing the sponsorship and supervision activities related to the IPO and listing, not a simple announcement or a financial report like an annual or interim report. This type of document is a specialized report related to capital market activities, specifically the sponsorship and underwriting process for an IPO. Given the content and nature, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is over 6,000 characters and contains substantive content, not just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2025-05-07 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.